Loading...

Discounted Cash Flow (DCF) Analysis Levered


GW Pharmaceuticals Plc

GW Pharmaceuticals Plc (GWPH)

Healthcare

Free Cash Flow

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue -----------
Revenue (%)
Operating Cash Flow -----------
Operating Cash Flow (%)
Capital Expenditure -----------
Capital Expenditure (%)
Free Cash Flow -----------

Weighted Average Cost Of Capital

Share price $ 102.65
Diluted Shares Outstanding 333.94
Cost of Debt
Tax Rate -1.30
After-tax Cost of Debt 0.12
Risk-Free Rate
Market Risk Premium
Cost of Equity 24.67
Total Debt 13.67
Total Equity 34,278.53
Total Capital 34,292.20
Debt Weighting 0.04
Equity Weighting 99.96
Wacc

Build Up Free Cash Flow

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue -----------
Operating Cash Flow -----------
Capital Expenditure -----------
Free Cash Flow -----------
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 24.67
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -
Equity Value -
Shares Outstanding 333.94
Equity Value Per Share -